|
Market Cap (19-May) $17,684,784 (923rd) |
Close (30-Jun) $0.125 |
Volume (30-Jun) 0 |
Shortsold (17-Apr) 8,415 (0.00%) (600th) |
|
52w High $0.064 |
52w Low $0.021 |
P/E - |
EPS 0 |
EMD released this announcement to the ASX on 14 April 2022, 9:47. The announcement is not marked as price sensitive, and is 5 page(s) in length and 453.07kb in size.
You can view all announcements from EMD and see how they appear on a price chart on the announcements page.
At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 600th as of the latest reported data (17 April 2025).
| Other Recent Announcements from EMD | |
|---|---|
| Trading Halt | 29 June 2023, 9:33 |
| Emyria Receives Ethics Approval for MDMA-assisted Therapy | 8 June 2023, 9:10 |
| Section 708A(5)(e) Notice | 10 May 2023, 18:37 |
| EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial | 14 April 2022, 9:47 |
| Clinitrials to lead multi-site Phase 3 trial for EMD-RX5 | 13 April 2022, 9:22 |
| Dosing Commences For EMD-RX5 Phase 1 Human Clinical Trial | 7 April 2022, 9:45 |
| Broker Briefing Presentation | 24 March 2022, 15:09 |
You must be logged in to post a reply.
Emyria 